US Stocks
Prelude Therapeutics Inc
Prelude Therapeutics Inc

Prelude Therapeutics Inc (PRLD)


  • $







Key Stats

Today Low/High$16.93 / $17.84
52 Week Low/High$15.31 / $95.38
Market Cap$831.2M

Company Details

Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s lead product candidates are designed to be oral, potent, and selective inhibitors of PRMT5. Prelude’s first clinical candidate, PRT543, is in Phase 1 development for advanced solid tumors and select myeloid malignancies. Prelude is also advancing PRT811, a second PRMT5 inhibitor optimized for high brain exposure, in a Phase 1 clinical trial including glioblastoma multiforme (GBM). The Company’s pipeline also includes its third clinical candidate, PRT1419, an orally available MCL1 inhibitor in Phase 1 development for patients with relapsed/refractory hematologic malignancies, and its two most advanced preclinical candidates, PRT2527, a CDK9 inhibitor, and PRT-SCA2, a SMARCA2 protein degrader.
OrganisationPrelude Therapeutics Inc
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is Prelude Therapeutics Inc (PRLD) share price today?

Can Indians buy Prelude Therapeutics Inc (PRLD) shares?

How can I buy Prelude Therapeutics Inc (PRLD) shares from India?

Can Fractional shares of Prelude Therapeutics Inc (PRLD) be purchased?

What are the documents required to start investing in Prelude Therapeutics Inc (PRLD) stocks?

We are a SEBI registered investement advisor